Motonobu Nakamura

6.1k total citations · 1 hit paper
184 papers, 3.4k citations indexed

About

Motonobu Nakamura is a scholar working on Surgery, Oncology and Dermatology. According to data from OpenAlex, Motonobu Nakamura has authored 184 papers receiving a total of 3.4k indexed citations (citations by other indexed papers that have themselves been cited), including 52 papers in Surgery, 52 papers in Oncology and 49 papers in Dermatology. Recurrent topics in Motonobu Nakamura's work include Bladder and Urothelial Cancer Treatments (31 papers), Cancer Immunotherapy and Biomarkers (25 papers) and Dermatology and Skin Diseases (22 papers). Motonobu Nakamura is often cited by papers focused on Bladder and Urothelial Cancer Treatments (31 papers), Cancer Immunotherapy and Biomarkers (25 papers) and Dermatology and Skin Diseases (22 papers). Motonobu Nakamura collaborates with scholars based in Japan, Germany and United States. Motonobu Nakamura's co-authors include Y. Tokura, Yu Sawada, Kenji Kabashima, Tasuku Honjo, Ryosuke Hino, Hiroaki Yagi, Yu Kato, Taku Okazaki, Natsuko Saito‐Sasaki and Ralf Paus and has published in prestigious journals such as Journal of Clinical Investigation, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Motonobu Nakamura

169 papers receiving 3.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Tumor cell expression of programmed cell death‐1 ligand 1 is a prognostic factor for malignant melanoma

2010 537 citations Kenji Kabashima, Motonobu Nakamura et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Motonobu Nakamura Japan	29	1.0k	872	871	748	454	184	3.4k
Stefano Calvieri Italy	34	800 0.8×	1.1k 1.2×	651 0.7×	900 1.2×	376 0.8×	248	4.2k
Mehrnaz Gharaee‐Kermani United States	34	700 0.7×	533 0.6×	486 0.6×	975 1.3×	363 0.8×	60	3.9k
Min Zheng China	30	1.1k 1.1×	853 1.0×	400 0.5×	1.0k 1.4×	138 0.3×	158	3.0k
V. Sibaud France	30	439 0.4×	1.4k 1.6×	1.7k 1.9×	542 0.7×	194 0.4×	158	3.5k
Ted Hamilton United States	35	585 0.6×	2.5k 2.9×	580 0.7×	648 0.9×	177 0.4×	55	3.9k
Yuji Shirakata Japan	36	1.1k 1.1×	830 1.0×	678 0.8×	1.3k 1.8×	293 0.6×	96	4.7k
Norito Katoh Japan	38	1.2k 1.2×	2.8k 3.2×	605 0.7×	520 0.7×	291 0.6×	263	5.1k
Karen Piper Hanley United Kingdom	44	1.1k 1.1×	593 0.7×	640 0.7×	2.2k 2.9×	1.3k 2.8×	119	5.7k
Martin Willheim Austria	38	1.7k 1.7×	297 0.3×	511 0.6×	704 0.9×	214 0.5×	89	4.1k
Joseph G. Morelli United States	31	411 0.4×	1.4k 1.6×	465 0.5×	492 0.7×	696 1.5×	122	3.7k

Countries citing papers authored by Motonobu Nakamura

Since Specialization

Citations

This map shows the geographic impact of Motonobu Nakamura's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Motonobu Nakamura with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Motonobu Nakamura more than expected).

Fields of papers citing papers by Motonobu Nakamura

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Motonobu Nakamura. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Motonobu Nakamura. The network helps show where Motonobu Nakamura may publish in the future.

Co-authorship network of co-authors of Motonobu Nakamura

This figure shows the co-authorship network connecting the top 25 collaborators of Motonobu Nakamura. A scholar is included among the top collaborators of Motonobu Nakamura based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Motonobu Nakamura. Motonobu Nakamura is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Takayama, Arimichi, et al.. (2025). Avelumab Maintenance Therapy for Advanced Urothelial Carcinoma with Low Tumor Burden. Cancers. 17(15). 2447–2447.

Minato, Akinori, Toshihisa Tomoda, Hiroyuki Masaoka, et al.. (2024). Organ-Specific Tumor Response to Enfortumab Vedotin for Metastatic Urothelial Carcinoma: A Multicenter Retrospective Study. Clinical Genitourinary Cancer. 22(5). 102148–102148. 3 indexed citations

Matsubara, Nobuaki, Hiroji Uemura, Atsushi Mizokami, et al.. (2024). Phase 3 Study of Talazoparib Plus Enzalutamide Versus Placebo Plus Enzalutamide as First‐Line Treatment in Patients With Metastatic Castration‐Resistant Prostate Cancer: TALAPRO ‐2 Japanese Subgroup Analysis. Cancer Medicine. 14(1). e70333–e70333.

Minato, Akinori, Takahito Negishi, Naotaka Sakamoto, et al.. (2023). Early Phase Persistent Changes in the White Blood Cell Fraction in Patients With Advanced Urothelial Carcinoma Treated With Pembrolizumab: A Multicenter Retrospective Study. Anticancer Research. 43(10). 4701–4708. 1 indexed citations

Minato, Akinori, Takahito Negishi, Naotaka Sakamoto, et al.. (2022). The Eosinophil Changes, Efficacy and Safety of Pembrolizumab in Advanced Urothelial Carcinoma Patients with an Older Age and a Poor Performance Status. OncoTargets and Therapy. Volume 15. 1321–1330. 1 indexed citations

Minato, Akinori, Takahito Negishi, Naotaka Sakamoto, et al.. (2022). Association Between Immune-Related Adverse Events and Efficacy and Changes in the Relative Eosinophil Count Among Patients with Advanced Urothelial Carcinoma Treated by Pembrolizumab. Cancer Management and Research. Volume 14. 1641–1651. 6 indexed citations

Sawada, Yu, Sayaka Sato, Reiko Hara, et al.. (2022). Prior antihistamine agent successfully impaired cutaneous adverse reactions to COVID‐19 vaccine. SHILAP Revista de lepidopterología. 5(5). 170–173. 1 indexed citations

Sawada, Yu, et al.. (2021). Macular‐type cutaneous adverse reaction due to atezolizumab and pembrolizumab. Journal of Cutaneous Immunology and Allergy. 5(2). 63–64.

Minato, Akinori, Takahito Negishi, Naotaka Sakamoto, et al.. (2021). The Association of Clinical Outcomes with Posttreatment Changes in the Relative Eosinophil Counts and Neutrophil-to-Eosinophil Ratio in Patients with Advanced Urothelial Carcinoma Treated with Pembrolizumab. Cancer Management and Research. Volume 13. 8049–8056. 17 indexed citations

10.

Negishi, Takahito, Naotaka Sakamoto, YooHyun Song, et al.. (2021). Organ-Specific Tumor Response to Pembrolizumab in Advanced Urothelial Carcinoma After Platinum-Based Chemotherapy. OncoTargets and Therapy. Volume 14. 1981–1988. 9 indexed citations

11.

Sawada, Yu, et al.. (2020). The Role of Cell Adhesion Molecule 1 (CADM1) in Cutaneous Malignancies. International Journal of Molecular Sciences. 21(24). 9732–9732. 16 indexed citations

12.

Negishi, Takahito, et al.. (2020). <p>Organ-Specific Therapeutic Effect of Paclitaxel and Carboplatin Chemotherapy After Platinum-Based Chemotherapy and Pembrolizumab for Metastatic Urothelial Carcinoma</p>. Research and Reports in Urology. Volume 12. 455–461. 2 indexed citations

13.

Negishi, Takahito, et al.. (2018). Efficacy and safety of third- and fourth-line targeted therapy in japanese patients with metastatic renal cell carcinoma: A retrospective analysis. Indian Journal of Urology. 34(2). 127–127. 2 indexed citations

14.

Saito, Ryuichi, Yu Sawada, Natsuko Saito‐Sasaki, et al.. (2018). Profile fluctuation of peripheral blood in advanced melanoma patients treated with nivolumab. The Journal of Dermatology. 45(12). 1452–1455. 5 indexed citations

15.

Saito‐Sasaki, Natsuko, Yu Sawada, Etsuko Okada, & Motonobu Nakamura. (2017). Drug eruption caused by enzalutamide: A case and literature review of androgen receptor inhibitor‐related drug eruptions. Australasian Journal of Dermatology. 59(2). e133–e134. 6 indexed citations

16.

Saito, Ryuichi, Yu Sawada, & Motonobu Nakamura. (2017). Two cases of eczematous drug eruption caused by oral tacrolimus administration. Contact Dermatitis. 77(2). 128–130. 3 indexed citations

17.

Sawada, Yu, et al.. (2012). Defective Epidermal Innate Immunity and Resultant Superficial Dermatophytosis in Adult T-cell Leukemia/Lymphoma. Clinical Cancer Research. 18(14). 3772–3779. 25 indexed citations

18.

Nakamura, Motonobu & Y. Tokura. (2011). Superficial Angiomyxoma on the Scrotum of a Child. Pediatric Dermatology. 28(2). 200–201. 9 indexed citations

19.

Yoshiki, Ryutaro, Kenji Kabashima, Jun‐ichi Sakabe, et al.. (2010). The Mandatory Role of IL-10–Producing and OX40 Ligand-Expressing Mature Langerhans Cells in Local UVB-Induced Immunosuppression. The Journal of Immunology. 184(10). 5670–5677. 37 indexed citations

20.

Sasaki, K., et al.. (1995). Macrophage colony stimulating factor inhibits experimental liver metastases from colon cancer.. PubMed. 15(4). 1235–9. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact